James, I follow your Substack because you’ve been writing about the WHO. A month ago you posted a Substack titled Ban the Jabs. The FDA 483s that Hedley has written about at Catalent, Lonza and Pfizer will help accomplish this.
It would be great if you cross post Hedley’s info so your readers can follow.
I know that - the new administrate meant he had to - do you not have anything to say about the content of the post? It matters not who the commissioner is, Gottlieb and Marks, as a very minimum, have blood on their hands - would you kindly comment on that, please James?
“In the event that [the] FDA ultimately determines that the Catalent facility was not operating in compliance with cGMP requirements at the time these batches were manufactured, Condition I in the Moderna COVID-19 Vaccine Letter of Authorization will be waived as to these batches,”
Calif resigned a few weeks ago.
https://www.healthcaredive.com/news/fda-sara-brenner-commissioner/738304/
James, I follow your Substack because you’ve been writing about the WHO. A month ago you posted a Substack titled Ban the Jabs. The FDA 483s that Hedley has written about at Catalent, Lonza and Pfizer will help accomplish this.
It would be great if you cross post Hedley’s info so your readers can follow.
I know that - the new administrate meant he had to - do you not have anything to say about the content of the post? It matters not who the commissioner is, Gottlieb and Marks, as a very minimum, have blood on their hands - would you kindly comment on that, please James?
Thank you.
The contaminants were a feature, not a bug.
My firm belief is that no vaccines or mRNA poisons should ever be taken until AFTER death.
Crixcyon— LOL. I wouldn't take that crap even after death.
Well because of Condition 1
“In the event that [the] FDA ultimately determines that the Catalent facility was not operating in compliance with cGMP requirements at the time these batches were manufactured, Condition I in the Moderna COVID-19 Vaccine Letter of Authorization will be waived as to these batches,”
https://www.bioprocessintl.com/facilities-capacity/catalent-hit-with-fda-483-at-bloomington-plant